454 related articles for article (PubMed ID: 19540112)
1. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
Owen DR; Walker JK; Jon Jacobsen E; Freskos JN; Hughes RO; Brown DL; Bell AS; Brown DG; Phillips C; Mischke BV; Molyneaux JM; Fobian YM; Heasley SE; Moon JB; Stallings WC; Joseph Rogier D; Fox DN; Palmer MJ; Ringer T; Rodriquez-Lens M; Cubbage JW; Blevis-Bal RM; Benson AG; Acker BA; Maddux TM; Tollefson MB; Bond BR; Macinnes A; Yu Y
Bioorg Med Chem Lett; 2009 Aug; 19(15):4088-91. PubMed ID: 19540112
[TBL] [Abstract][Full Text] [Related]
2. Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.
Hughes RO; Walker JK; Rogier DJ; Heasley SE; Blevis-Bal RM; Benson AG; Jacobsen EJ; Cubbage JW; Fobian YM; Owen DR; Freskos JN; Molyneaux JM; Brown DL; Acker BA; Maddux TM; Tollefson MB; Moon JB; Mischke BV; Rumsey JM; Zheng Y; MacInnes A; Bond BR; Yu Y
Bioorg Med Chem Lett; 2009 Sep; 19(17):5209-13. PubMed ID: 19631533
[TBL] [Abstract][Full Text] [Related]
3. Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring system.
Hughes RO; Walker JK; Cubbage JW; Fobian YM; Rogier DJ; Heasley SE; Blevis-Bal RM; Benson AG; Owen DR; Jacobsen EJ; Freskos JN; Molyneaux JM; Brown DL; Stallings WC; Acker BA; Maddux TM; Tollefson MB; Williams JM; Moon JB; Mischke BV; Rumsey JM; Zheng Y; Macinnes A; Bond BR; Yu Y
Bioorg Med Chem Lett; 2009 Aug; 19(15):4092-6. PubMed ID: 19539468
[TBL] [Abstract][Full Text] [Related]
4. 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6.
Duan H; Zheng J; Lai Q; Liu Z; Tian G; Wang Z; Li J; Shen J
Bioorg Med Chem Lett; 2009 May; 19(10):2777-9. PubMed ID: 19375311
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).
Hughes RO; Rogier DJ; Jacobsen EJ; Walker JK; Macinnes A; Bond BR; Zhang LL; Yu Y; Zheng Y; Rumsey JM; Walgren JL; Curtiss SW; Fobian YM; Heasley SE; Cubbage JW; Moon JB; Brown DL; Acker BA; Maddux TM; Tollefson MB; Mischke BV; Owen DR; Freskos JN; Molyneaux JM; Benson AG; Blevis-Bal RM
J Med Chem; 2010 Mar; 53(6):2656-60. PubMed ID: 20196613
[TBL] [Abstract][Full Text] [Related]
6. New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.
Feixas J; Giovannoni MP; Vergelli C; Gavaldà A; Cesari N; Graziano A; Dal Piaz V
Bioorg Med Chem Lett; 2005 May; 15(9):2381-4. PubMed ID: 15837329
[TBL] [Abstract][Full Text] [Related]
7. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.
Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Linget JM; Kirilovsky J; Hyafil F; Labaudinière R
J Med Chem; 2003 Oct; 46(21):4533-42. PubMed ID: 14521415
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors.
Jiang W; Alford VC; Qiu Y; Bhattacharjee S; John TM; Haynes-Johnson D; Kraft PJ; Lundeen SG; Sui Z
Bioorg Med Chem; 2004 Mar; 12(6):1505-15. PubMed ID: 15018924
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
Xia G; Li J; Peng A; Lai S; Zhang S; Shen J; Liu Z; Chen X; Ji R
Bioorg Med Chem Lett; 2005 Jun; 15(11):2790-4. PubMed ID: 15878277
[TBL] [Abstract][Full Text] [Related]
10. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.
Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Kirilovsky J; Hyafil F; Labaudinière R
J Med Chem; 2003 Oct; 46(21):4525-32. PubMed ID: 14521414
[TBL] [Abstract][Full Text] [Related]
11. Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule.
Bunnage ME; Mathias JP; Wood A; Miller D; Street SD
Bioorg Med Chem Lett; 2008 Dec; 18(23):6033-6. PubMed ID: 18951784
[TBL] [Abstract][Full Text] [Related]
12. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.
Deninno MP; Andrews M; Bell AS; Chen Y; Eller-Zarbo C; Eshelby N; Etienne JB; Moore DE; Palmer MJ; Visser MS; Yu LJ; Zavadoski WJ; Michael Gibbs E
Bioorg Med Chem Lett; 2009 May; 19(9):2537-41. PubMed ID: 19339180
[TBL] [Abstract][Full Text] [Related]
13. Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.
Kim YH; Choi H; Lee J; Hwang IC; Moon SK; Kim SJ; Lee HW; Im DS; Lee SS; Ahn SK; Kim SW; Han CK; Yoon JH; Lee KJ; Choi NS
Bioorg Med Chem Lett; 2008 Dec; 18(23):6279-82. PubMed ID: 18976905
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.
Wang G; Liu Z; Chen T; Wang Z; Yang H; Zheng M; Ren J; Tian G; Yang X; Li L; Li J; Suo J; Zhang R; Jiang X; Terrett NK; Shen J; Xu Y; Jiang H
J Med Chem; 2012 Dec; 55(23):10540-50. PubMed ID: 23137303
[TBL] [Abstract][Full Text] [Related]
15. Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.
Yang SW; Smotryski J; McElroy WT; Tan Z; Ho G; Tulshian D; Greenlee WJ; Guzzi M; Zhang X; Mullins D; Xiao L; Hruza A; Chan TM; Rindgen D; Bleickardt C; Hodgson R
Bioorg Med Chem Lett; 2012 Jan; 22(1):235-9. PubMed ID: 22142545
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
[TBL] [Abstract][Full Text] [Related]
17. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
[TBL] [Abstract][Full Text] [Related]
18. The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
Aspiotis R; Deschênes D; Dubé D; Girard Y; Huang Z; Laliberté F; Liu S; Papp R; Nicholson DW; Young RN
Bioorg Med Chem Lett; 2010 Sep; 20(18):5502-5. PubMed ID: 20709547
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitors.
Lanter JC; Sui Z; Macielag MJ; Fiordeliso JJ; Jiang W; Qiu Y; Bhattacharjee S; Kraft P; John TM; Haynes-Johnson D; Craig E; Clancy J
J Med Chem; 2004 Jan; 47(3):656-62. PubMed ID: 14736245
[TBL] [Abstract][Full Text] [Related]
20. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
Malamas MS; Ni Y; Erdei J; Stange H; Schindler R; Lankau HJ; Grunwald C; Fan KY; Parris K; Langen B; Egerland U; Hage T; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Hoefgen N; Brandon NJ
J Med Chem; 2011 Nov; 54(21):7621-38. PubMed ID: 21988093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
